JPH06340549A - Therapeutic agent for feline respiratory organ disease and therapeutic method using the therapeutic agent - Google Patents

Abstract

PURPOSE:To obtain a feline respiratory disease therapeutic agent exhibiting remarkable effects, even when administered through routes except veins, and capable of reducing the labor load of a person on the therapeutic duty and the economical load of an owner. CONSTITUTION:The characteristic of this feline respiratory organ disease therapeutic agent comprises containing as an active ingredient an interferon produced by a microorganismic or animal cell into which an HuIFN-related gene collected from cells originated from human has been introduced. The HuIFN can mainly be classified into three kind types consisting of HuIFN-alpha, HuIFN-beta and HuIFN-gamma on the basis of antigenicity. Only one kind type of the HuIFN may be used, or a combination of different kind types of the HuIFN may be used. Even when any HuIFN is used, it is desirable to use the HuIFN having as high specific activity as possible. When orally administered, a partially or wholly purified product having a specific activity of approximately 10<5> international units/mg of protein is desirable, and when parenterally administered, a purified product having a specific activity of approximately 10<7> international units/mg of protein is desirable.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to veterinary medicine for cats, especially human interferon (hereinafter referred to as "H").
It may be abbreviated as "uIFN". ) Is an active ingredient for treating respiratory diseases in cats.

[0002]

2. Description of the Related Art In recent years, with the enrichment of life, more and more people are demanding the compassion for pet animals. Among pet animals, cats have been one of the most popular pet animals along with dogs since ancient times, and a wide variety of breeds have been created by breeding over many years, and nowadays a surprisingly expensive breed also appears. It became so. Due to the recent tendency as described above, the number of cats housed at home is also increasing dramatically, and the number of cats brought to veterinary hospitals is rapidly increasing accordingly.

Cats handled in veterinary hospitals suffer from various infectious diseases, especially respiratory diseases of cats, so-called "cat colds", except those requiring surgical treatment due to trauma or fracture. There are many cases of being brought in. The main cause of a cat cold is thought to be the respiratory tract infection virus, and when the cat is infected, it often causes coughing, runny nose, salivation, fever, upper respiratory tract inflammation, pneumonia, stomatitis, glossitis, conjunctivitis, granulitis, It causes common cold-like symptoms such as tongue ulcer, nasal end ulcer, systemic skin ulcer, turbinate ulcer, diarrhea, vomiting, decreased appetite, decreased activity. In particular, when the sick animal is infected with the feline immunodeficiency virus (hereinafter sometimes abbreviated as "FIV"), these various symptoms become more prominent and rapidly debilitate. At present, there is no such cure for feline viral diseases, including feline respiratory diseases, and even in the case of respiratory diseases, nutritional therapy with fluid replacement is applied to relieve dehydration and restore physical strength, The actual situation is that only symptomatic treatment is performed, such as administration of antibiotics to prevent complex infections or secondary infections, or simply removal of viscous secretions.

Recently, an attempt was made to treat respiratory diseases in cats by intravenously administering recombinant feline interferon in the order of several million international units, and it was confirmed that the efficacy was to some extent. Tomiya Uchino Etc., "Small Animal Clinic", Volume 11,
No. 6, 11-25 (1992). However, in order to effectively carry out this method, a large amount of feline interferon must be administered to the sick animal, which greatly increases the financial burden on the owner. That is, even if it is a genetically engineered type, bioactive polypeptides such as interferon are generally very expensive at present, and if a large amount of feline interferon is used for a long period of time, the economical burden on the owner increases. Is inevitable. Further, in general, cats are nervous, vigilant, and difficult to handle. Therefore, from the standpoint of the veterinarian who is actually in charge of treatment, it is preferable to administer a method other than intravenous to obtain a marked effect.

Therefore, there is a demand for the development of a method capable of treating respiratory diseases in cats simply and effectively and with less economical burden on the owner.

[0006]

SUMMARY OF THE INVENTION In view of such a situation,
The object of the present invention is to provide a therapeutic agent for respiratory diseases in cats, which shows remarkable effects even when administered by a route other than intravenous, and which requires less labor and burden on the person in charge of treatment and economical burden on the owner. Especially.

[0007]

[Means for Solving the Problems] In order to solve such a problem, the present inventors have conducted diligent research and found that HuIFN
Cough, runny nose, salivation, fever, upper respiratory tract inflammation, pneumonia, stomatitis, glossitis, conjunctivitis associated with respiratory disease in cats in small doses.
Granulitis, tongue ulcer, nose end ulcer, systemic skin ulcer,
It was found to be highly effective in improving general clinical symptoms such as turbinate ulcer, diarrhea, vomiting, loss of appetite and loss of activity. Moreover, the administration route is not limited to intravenous administration,
It can also be administered parenterally or orally by a route other than intravenous.

[0008] That is, the gist of the present invention is a therapeutic agent for respiratory diseases in cats containing HuIFN as an active ingredient.

Although interferon was originally found as a substance having an antiviral effect, it is highly species-specific, and in order to treat a certain animal, it is effective only if the interferon is derived from an animal of the same species. It has been said that there is no. Therefore, it was completely unexpected that human-derived interferon is effective in treating respiratory diseases in cats.

[0010]

When the therapeutic agent of the present invention is administered to a cat suffering from a respiratory disease, HuIFN, which is an active ingredient, acts effectively, resulting in cough, runny nose, salivation and fever associated with the respiratory disease of a cat. , Upper respiratory tract inflammation, pneumonia, stomatitis, glossitis, conjunctivitis,
Granulitis, tongue ulcer, nose end ulcer, systemic skin ulcer,
Improve general clinical symptoms such as turbinate ulcer, diarrhea, vomiting, decreased appetite, decreased activity.

HuIFN has a high therapeutic effect on respiratory diseases in cats, and is usually about 0.00 per kg of cat body weight.
Very small doses of 5 to 5,000 international units are sufficient.

HuIFN is remarkably effective in the treatment of respiratory diseases in cats either parenterally or orally by a route other than intravenous.

The present invention will be described in detail below with reference to examples.

The cat referred to in the present invention is an animal belonging to the so-called feline genus of cats, and is susceptible to respiratory tract infection viruses such as feline herpes virus and feline calicivirus, which are the main causes of respiratory diseases in cats, Infected with this, or further complex or secondary infection with FIV, mycoplasma, bacteria, parasites, etc., cough, runny nose, salivation, fever, upper respiratory tract inflammation, pneumonia, stomatitis, glossitis, conjunctivitis, granulitis. ,
Tongue ulcer, nose end ulcer, systemic skin ulcer, turbinate ulcer, diarrhea, vomiting, decreased appetite, general animal showing two or more general clinical symptoms selected from decreased activity, usually,
It is intended to treat all the cats.

The therapeutic agent for feline respiratory diseases according to the present invention is a human-derived cell or H collected from a human-derived cell.
The active ingredient is interferon produced by a microorganism or animal cell into which a uIFN-related gene has been introduced. Today, HuIFN is based on its difference in antigenicity,
Mainly HuIFN-α, HuIFN-β, HuIFN
It is classified into three types called γ. Although there are some differences in the therapeutic effects on respiratory diseases in cats, any of them can be used in the present invention. At that time, only one type of HuIFN may be used, or two or more types of HuIFN having different types may be used in combination. Which H
Even in the case of uIFN, it is desirable to use one having as high a specific activity as possible. For oral administration, the specific activity is about 10 ⁵
Partial purified products and purified products with more than international unit / mg protein,
For parenteral administration, a purified product of about 10 ⁷ international units / mg protein or more is desirable.

The present inventors have tested these Hu
Of IFNs, HuIFN-α, especially BALL-
Produced by human lymphoblastoid cell lines such as 1 cell and Namalwa cell, and white blood cells separated from human blood,
“Natural HuIFN-α” is characterized by a markedly high therapeutic effect on respiratory diseases in cats and few side effects. In particular, HuIFN-α derived from BALL-1 cells
Is a HuIFN such as subtype α2 or subtype α8
It contains a subtype of -α in a very well-balanced manner and has the best effect when used in the present invention. Recombinant HuIFN generally has a therapeutic effect on the native HuIFN.
Inferior to IFN, side effects tended to be rather strong.

The therapeutic agent for feline respiratory disease according to the present invention is not only in the form of HuIFN alone, but also in the case of HuIFN and other physiologically acceptable ones, such as carrier, excipient,
It includes a diluent, an immunostimulant, a stabilizer, and, if necessary, a composition as a composition with an antipyretic agent, an anti-inflammatory agent, an antibacterial agent, a digestive agent, a nutritional supplement, a feed and the like. Further, the therapeutic agent of the present invention also includes a drug in a dosage unit form, and the drug in the dosage unit form means Hu which is an active ingredient of the present invention.
IFN, for example, in a daily, or an integral multiple (up to 4 times) or equivalent amount (up to 1/40) thereof, in a physically separate, unitary dosage form suitable for administration. Means a drug. Examples of the drug having such a dosage form include injections, liquids, oral gels, powders, granules, tablets, capsules and sublingual agents.

The dose and usage of the therapeutic agent for feline respiratory diseases according to the present invention will be explained.
The desired therapeutic effect can be obtained by oral or parenteral administration. Specifically, it varies depending on the type of cat, the type of causative virus, the symptoms, the dose, the usage, the type of HuIFN used, etc. 0.005
To 5,000 international units / time, preferably about 0.5 to 50 international units / time, more preferably about 1 to 20 international units / time HuIFN 1 to 3 times a day or 1 to 1 time a week. It may be administered 5 times for about 1 day to 1 month.

To administer the therapeutic agent of the present invention orally, the therapeutic agent is prepared into an orally administrable form such as a solution, a troche, a powder, a granule, a tablet, a sublingual preparation, and a bait.
If necessary, it may be inserted into the oral cavity, the nasal cavity, the esophagus, or the stomach according to a conventional method while using an appropriate administration aid such as an oral administration device or a gastric tube. Further, for parenteral administration, the injection according to the present invention is applied intradermally to the cat,
It may be injected subcutaneously, intramuscularly, intravenously or intraperitoneally. The inventors of the present invention tested, when the dose is less than the above range, it is difficult to obtain the desired therapeutic effect, and conversely, when the dose is more than the above range, antibody production and side effects become remarkable, or the therapeutic effect is compared to the owner. Since the economic burden of the above may become large, the above range is set as the best value.

Comparing individual routes of administration from the viewpoint of therapeutic effect and easiness of administration, oral administration has the advantage that it can be easily carried out in general households, but a certain amount of Hu is used.
The drawback is that it is difficult to administer IFN accurately. As a result, it may be necessary to administer more HuIFN than originally required, or the treatment may take a relatively long period of time, increasing the financial burden on the owner. On the contrary,
Although parenteral administration has the drawback that it is difficult to carry out in a general household, it has the advantage that a prescribed amount of HuIFN can be accurately administered to the patient and that the desired therapeutic effect can be achieved with the minimum necessary amount of HuIFN. As a result, the sick animal can be completely cured in a relatively short period of time, and the economic burden on the owner can be reduced. In particular, when the therapeutic agent of the present invention is administered intradermally, subcutaneously or intramuscularly, a smaller amount of HuI is used than oral administration or parenteral administration by a route other than the above.
FN is sufficient, it is easy to administer, and the financial burden on the owner is also minimal. This was particularly remarkable in the case of native HuIFN-α, particularly HuIFN-α derived from BALL-1 cells.

[0021] Throughout the present specification, the activity of HuIFN is measured by the microtiter method to determine the degree to which HuIFN suppresses the cytopathic modification of FL cells by Sindbis virus, and the measured value is the international standard of HuIFN by the World Health Organization. Based on the product "Ga23-901-532", it is converted into "international units" and displayed.

Hereinafter, the present invention will be described more specifically based on a few examples.

[0023]

Example 1 Dry injection: According to the method described in Japanese Patent Publication No. 56-54158, BALL-1 cells grown in a hamster body were made to act on Sendai virus in a culture medium to induce interferon. The culture medium was centrifuged to obtain a supernatant, which was concentrated, and affinity chromatography using phenyl sepharose was applied to the concentrate to obtain a partially purified HuIFN having a specific activity of about 10 ⁶ international units / mg protein. . Next, this partially purified HuIFN was further purified by affinity chromatography using "NK-2 Sepharose" manufactured by Celtec in which a monoclonal anti-HuIFN-α antibody was bound to a water-insoluble carrier by a conventional method, and then feline serum albumin. By applying gel filtration chromatography equilibrated with phosphate buffer (pH 7.0) containing about 0.1 mg / ml, a specific activity of about 2 × 10 ⁸ international units / mg of purified HuIFN-α is contained. HuIFN
-A solution was obtained.

Purified HuIFN-prepared in this way
Membrane concentration of α to about 5 mg protein / ml, 1% (w /
v) Feline serum albumin and 0.01M phosphate buffer (pH
It was diluted in a physiological saline solution containing 7.0) so that the HuIFN-α concentration would be 15 international units / ml, sterilized by membrane filtration, and then aseptically filled in 1 ml vials and lyophilized.

This product contains purified HuIFN-α derived from BALL-1 cells as an active ingredient, and serum albumin as a vehicle is derived from cats. It is useful as an agent.

[0026]

[Example 2 Dry injection] H produced by causing Sendai virus to act on leukocytes separated from human blood by a conventional method
uIFN, K. Cantel, etc.
"The Journal of General Virology (The Journal of General V
irology) ”, Vol. 39, pp. 541-543 (1978), and purified to a specific activity of about 2 × 10 ⁶ international units / mg protein partially purified HuI.
I got FN. Then, this partially purified HuIFN was further purified by antibody chromatography using a monoclonal anti-HuIFN-α antibody as in Example 1, and
By applying gel filtration chromatography equilibrated with a phosphate buffer (pH 7.0) containing about 0.1 mg / ml of pharmacopoeia, purified HuIFN with a specific activity of about 2 × 10 ⁸ international units / mg. HuIF containing α
An N-α solution was obtained.

Purified HuIFN-prepared in this way
Membrane concentration of α to about 5 mg protein / ml, 1% (w /
v) Pharmacopoeial purified gelatin and 0.01M phosphate buffer (pH
It was diluted in a physiological saline solution containing 7.0) so that the HuIFN-α concentration was 20 international units / ml, sterilized by membrane filtration, and then aseptically filled in vials in an amount of 1 ml and freeze-dried.

Purified Hu derived from human leukocytes as an active ingredient
Although this product containing IFN-α is slightly inferior to the injection of Example 1 in therapeutic effect and side effect, it is useful as an injection for treating respiratory diseases in cats.

[0029]

Example 3 Dry Injection BAL as in Example 1
Purified HuIFN-α prepared by allowing Sendai virus to act on L-1 cells was added to a physiological saline containing 3% (w / v) feline serum albumin and 0.1 M phosphate buffer (pH 7.0) HuIFN-. α concentration is 20,000 international units /
After diluting to have a volume of 1 ml, sterilizing by filtration through a membrane, 1 ml was filled in each vial and freeze-dried.

Like the injection of Example 1, this product contains purified HuIFN-α derived from BALL-1 cells as an active ingredient, and the serum albumin used as a vehicle is derived from cats. , Useful as an injection for treating respiratory diseases in cats.

[0031]

Example 4 Gel Oral Agent A solution containing 1% (w / v) of bovine serum albumin in distilled water and containing the partially purified HuIFN derived from BALL-1 cells prepared by the method of Example 1 in the solution. Was added to obtain a HuIFN solution containing 300 international units of HuIFN per gram. This solution 32.
0.5 parts by weight of “Tween 80” to 0 parts by weight of 15.0
Dissolve and mix in 1 part by weight of ethanol, and further add 15.0 parts by weight of triethanolamine to the mixture.
After dissolving in 1 part by weight of glycerin and mixing, a small amount of triethanolamine was added to obtain a nearly neutral gel-like preparation containing about 100 international units of HuIFN per ml.

H derived from BALL-1 cells as an active ingredient
The product containing uIFN is a gel-type oral preparation for treating respiratory diseases, which has an appropriate residence time in the oral cavity and is easily drinkable by patients.

[0033]

[Example 5 Powder] Partially purified H derived from human leukocytes prepared by the method of Example 2 in 100 parts by weight of a high-purity anhydrous crystalline maltose product "Finetose" manufactured by Hayashibara Co., Ltd.
2 parts by weight of uIFN (about 10 ⁶ international units / ml) was uniformly sprayed, vacuum-dried, crushed, and sieved to give a particle size of 10
A powder of 0 to 500 microns was obtained. The powdery substance was further uniformly mixed with an appropriate amount of "FINETOSE" to obtain a powder containing about 100 international units of HuIFN per gram.

This product has an appropriate retention time in the oral cavity and excellent storage stability, and is useful as a powder for treating respiratory diseases in cats. This product has a moderate sweetness, is a powder that can be administered to the sick of animals and administered to the oral cavity of cats without causing irritation.

[0035]

Example 6 Granules An aqueous solution containing 100 parts by weight of high-purity anhydrous crystalline maltose product “Finetose” manufactured by Hayashibara Co., Ltd. and partially purified HuIFN derived from BALL-cells prepared by the method of Example 1 (about 30 After uniformly mixing 15 parts by weight (1,000 international units / ml), the mixture was tableted to obtain granules.

This product contains about 4 and 4 HuIFN per gram.
It contains 00 international units, has excellent storage stability, and is useful as a powder for treating respiratory diseases in cats. In addition, this product has a moderate sweetness and is administered to the cat's oral cavity with less irritation,
It is a granule that can be easily given to patients.

Next, a clinical test conducted using the therapeutic agent of the example will be described.

[0038]

[Experimental Example 1 Clinical study] Cough, runny nose, salivation, fever, upper respiratory tract inflammation, pneumonia, stomatitis, glossitis, conjunctivitis, granulitis, tongue ulcer, nose tip ulcer, systemic skin ulcer, nasal concha ulcer , The diarrhea, vomiting, decreased appetite, decreased activity, etc. were brought to the veterinary hospital, and the dry injection of Example 1 was actually administered to 52 Kanekos judged to have respiratory disease as a result of the diagnosis. The effects and side effects of the therapeutic agent according to the present invention were evaluated by observing the progress thereof.

That is, the respiratory disease was diagnosed from the general clinical findings at the time of the first medical examination, and the result of the virus test was FIV.
Male cats presumed to be 1 to 6 years old with antibody positive test
Targeting 3 and 19 female cats, the weight k
The dry injection of Example 1 was administered by injection once a day for 1 week at a dose of about 1 to 20 international units / g / g.
Careful observation of the course immediately after the start of administration, together with the dose, showed general condition, dehydration, appetite, water desire, activity, runny nose, cough, diarrhea, salivation, conjunctivitis, stomatitis, nasal end ulcer, respiratory mode, vomiting, etc. Fourteen general clinical findings were recorded. As a result of the virus test, most of the affected animals were suspected to have a combined infection with feline herpesvirus and / or feline calicivirus.

Clinical experiments were mainly conducted by a veterinarian, and the dose of interferon and the number of administrations were adjusted while observing the appearance, symptoms, side effects, etc. of the affected animals. Then, when the administration was completed, the results were compiled and the effectiveness of the therapeutic agent according to the present invention was determined based on the following criteria. That is,
If all symptoms return to normal within 5 days, it is said to be “effective”. Stomatitis is improved from the initial diagnosis, and other three or more symptoms are improved, or stomatitis does not develop, If the other 5 items are improved, the result is “effective”. Stomatitis is not improved, but if the other 4 items or more are improved, the result is “slightly effective”. And, if the symptom worsens, it is said to be "worse".

As a result of clinical experiments, in all clinical cases, cough, runny nose, salivation and diarrhea stopped within 3 days immediately after the start of administration, and the body temperature recovered to the normal range of 37 ° C. Within 1 week after the start of administration, upper respiratory tract inflammation, stomatitis,
Conjunctivitis and nasal ulcer were significantly improved or repaired, and appetite and activity were improved. Judgment based on the above criteria, out of a total of 52 clinical cases, 28 cases were "excellent", 15 cases were "effective", 5 cases were "slightly effective", 4 cases were "ineffective",
"Exacerbation" was 0, and "outstanding" and "effective" out of 52 cases
Or, the clinical cases judged to be “slightly effective” reached about 92%. Moreover, no particular side effect was observed during the administration period, demonstrating that the therapeutic agent according to the present invention is extremely effective and safe for the treatment of respiratory diseases in cats. In addition, when blood tests were continued for some of the sick animals even after being completely cured, no antibody production, which was considered to be caused by HuIFN-α, was detected. This suggests that the therapeutic agent according to the present invention is safe for repeated administration to the same cat for the purpose of treating respiratory diseases in cats.

Based on the above findings, Examples 2, 4 and 5
When the same clinical experiment was carried out for the above embodiment, extremely excellent therapeutic results were obtained, that is, about 70% or more by parenteral administration and about 60% or more by oral administration. The efficacy rate of oral administration is slightly lower than that of parenteral administration, but much higher than that of ordinary drugs. Parenteral administration relied on intradermal, subcutaneous, intramuscular, intravenous or intraperitoneal injections, but the dose was so small that it took only a short time to insert the injection needle, and The administration could be completed with almost one insertion without the rampage.

The partially purified HuIFN and the purified HuIFN- used in the embodiments of Examples 1, 2, 4 and 5.
When α was tested for acute toxicity in healthy cats,
All were found to have extremely low toxicity to cats.

[0044]

[Experimental example 2 clinical test] Kaneko 4 showing the same symptoms as the one used in Experimental example 1 and diagnosed as a respiratory disease.
The effect and side effects were evaluated by administering the dry injection of Example 3 to 0 animals and observing the progress after administration.

That is, respiratory disease was diagnosed based on the general clinical findings at the first examination, and the result of the virus test showed that
Male cat 1 presumed to be 1 to 6 years old with antibody positive
Nine and 21 female cats were weighed subcutaneously on their backs.
The dried injection of Example 3 was administered by injection once a day for 1 week at a dose of about 500 to 5,000 international units / g / g. The course was carefully observed immediately after the start of administration, and as with Example 1, 14 general clinical findings were recorded together with the dose.

Clinical experiments were mainly conducted by a veterinarian, and the dose of interferon and the frequency of administration were adjusted while observing the appearance, symptoms, side effects, etc. of the sick animal. Then, when the administration was completed, the results were compiled and the effectiveness of this product was determined based on the same criteria as in Experimental Example 1.

As a result of the clinical test, in all clinical cases, improvement of clinical symptoms was observed immediately after the initiation of administration, cough, runny nose, salivation and diarrhea were stopped within 3 days, and the body temperature was in the normal range of 37 ° C. Recovered. Within 1 week after the start of administration, upper respiratory tract inflammation, stomatitis, conjunctivitis, and nasal ulcer were markedly improved or repaired, and appetite and activity were improved.

Judgment was carried out based on the above-mentioned criteria, and out of all 40 clinical cases, "serious effect" was 25 and "effective".
11 cases, “slightly effective” in 2 cases, “ineffective” in 2 cases, and “exacerbation” in 0 cases, clinically judged to be “excellent”, “effective” or “slightly effective” out of all 40 cases The number of cases reached 95%.
Moreover, no particular side effects were observed during the administration period,
It has been proved that the therapeutic agent according to the present invention is extremely effective and safe for the treatment of respiratory diseases in cats. In addition, when blood tests were continued for some of the sick animals even after being completely cured, no antibody production, which was considered to be caused by HuIFN-α, was detected. This suggests that the therapeutic agent according to the present invention is safe for repeated administration of about 500 to 5,000 international units per kg body weight to the same cat for the purpose of treating respiratory diseases in cats. There is.

Based on the above findings, the same clinical experiment was conducted for the embodiment of Example 6, and it was found that about 7
An extremely excellent treatment result of 5% or more was obtained. The efficacy rate of oral administration is slightly lower than that of parenteral administration, but much higher than that of ordinary drugs.

Regarding the partially purified HuIFN and the purified HuIFN-α used in the embodiments of Examples 3 and 6,
An acute toxicity test in healthy cats revealed that the toxicity to cats was extremely low.

[0051]

[Acute toxicity test] 0.01M phosphate buffer (pH 7.0)
Partially purified HuIFN or purified HuIFN-derived from BALL-1 cells or human leukocytes prepared by the method of Example 1 or Example 2 in physiological saline containing
α and, in this order, the final concentration of each is 0.1%
(W / v) and 1 × 10 ⁶ international units / ml were dissolved. The four kinds of solutions thus obtained are 1 to 2 after birth.
For 4 groups of 5 healthy hybrid cats / group estimated to be 1 year, an amount of physiology equivalent to 1 × 10 ⁶ international units of HuIFN, which is 20,000 times the maximum dose of the present invention, per kg body weight. Saline was subcutaneously or orally administered, and the course after administration was observed. To the control group, the same amount of physiological saline prepared in the same manner as above was administered by the same route except that HuIFN was not dissolved.

As a result, no significant difference was observed between the test group and the control group in any of the HuIFNs, and there were no particular changes in post-administration deaths, general conditions before and after administration, body weight, and food consumption. There wasn't. This means that HuIFN
However, it has been suggested that it is extremely less toxic when administered to cats.

[0053]

INDUSTRIAL APPLICABILITY As described above, since the therapeutic agent for feline respiratory diseases according to the present invention contains HuIFN as an active ingredient, it causes cough, runny nose, salivation, fever,
Upper respiratory tract inflammation, pneumonia, stomatitis, glossitis, conjunctivitis, granular adenitis, tongue ulcer, nose ulcer, systemic skin ulcer, turbinate ulcer, diarrhea, vomiting, decreased appetite, decreased activity, etc. It is extremely effective in improving symptoms.

Furthermore, HuIFN, which the therapeutic agent of the present invention contains as an active ingredient, is safe even when administered to a large amount of sick animals, and exerts a marked effect even in a small dose. Greatly reduce the financial burden. For the same reason, when using the therapeutic agent of the present invention, it is not necessary to administer interferon intravenously to a patient,
The intended effect can also be obtained by oral administration or parenterally by a route other than intravenous such as intracutaneous, subcutaneous and intramuscular. As a result, a predetermined amount of HuIFN can be reliably and easily administered to a nervous and vigilant cat, and the labor and burden of a veterinarian or other person in charge of treatment can be significantly reduced.

The above-mentioned effects are obtained by using natural type H as an active ingredient.
uIFN-α, especially Hu from BALL-1 cells
By using IFN-α in combination, it becomes more remarkable.

The present invention is an invention having such remarkable effects and is a great invention that contributes to the field.

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁵ Identification code Office reference number FI technical display area A61K 9/14 X 9455-4C

Claims (11)

[Claims] 1. A therapeutic agent for respiratory diseases in cats, which comprises human interferon as an active ingredient. 2. The therapeutic agent for respiratory diseases in cats according to claim 1, wherein the human interferon is human interferon-α. 3. The therapeutic agent for respiratory diseases in cats according to claim 1 or 2, wherein the human interferon is a natural human interferon. 4. The therapeutic agent for respiratory diseases in cats according to claim 1, 2 or 3, wherein the human interferon is natural human interferon-α produced by a human lymphoblastoid cell line. 5. The treatment of respiratory diseases in cats according to claim 1, wherein human interferon is contained in an amount of about 0.005 to 5,000 international units per kg body weight of the cat to which it is administered. Agent. 6. The therapeutic agent for respiratory diseases in cats according to claim 1, 2, 3, 4, or 5, wherein the dosage form is an oral dosage form or a parenteral dosage form. 7. A human body weight of 1 kg of human interferon
A method for treating a respiratory disease in a cat, which comprises administering about 0.005 to 5,000 international units per administration. 8. The method for treating respiratory diseases in cats according to claim 7, wherein the human interferon is human interferon-α. 9. The method for treating a respiratory disease in a cat according to claim 7, wherein the human interferon is a natural human interferon. 10. Human interferon-natural human interferon-α produced by a human lymphoblastoid cell line.
10. The method for treating a respiratory disease of a cat according to claim 7, 8 or 9. 11. The method for treating respiratory diseases in cats according to claim 7, 8, 9 or 10, wherein the dosage form is an oral dosage form or a parenteral dosage form.